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ORIGINAL RESEARCH

Systolic Blood Pressure Response in SPRINT (Systolic Blood Pressure
Intervention Trial) and ACCORD (Action to Control Cardiovascular
Risk in Diabetes): A Possible Explanation for Discordant Trial Results
Chenxi Huang, PhD; Sanket S. Dhruva, MD; Andreas C. Coppi, PhD; Frederick Warner, PhD; Shu-Xia Li, PhD; Haiqun Lin, PhD;
Khurram Nasir, MD, MPH; Harlan M. Krumholz, MD, SM

Background-—SPRINT (Systolic Blood Pressure Intervention Trial) and the ACCORD (Action to Control Cardiovascular Risk in
Diabetes) blood pressure trial used similar interventions but produced discordant results. We investigated whether differences in
systolic blood pressure (SBP) response contributed to the discordant trial results.
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Methods and Results-—We evaluated the distributions of SBP response during the ﬁrst year for the intensive and standard
treatment groups of SPRINT and ACCORD using growth mixture models. We assessed whether signiﬁcant differences existed
between trials in the distributions of SBP achieved at 1 year and the treatment-independent relationships of achieved SBP with
risks of primary outcomes deﬁned in each trial, heart failure, stroke, and all-cause death. We examined whether visit-to-visit
variability was associated with heterogeneous treatment effects. Among the included 9027 SPRINT and 4575 ACCORD
participants, the difference in mean SBP achieved between treatment groups was 15.7 mm Hg in SPRINT and 14.2 mm Hg in
ACCORD, but SPRINT had signiﬁcantly less between-group overlap in the achieved SBP (standard deviations of intensive and
standard groups, respectively: 6.7 and 5.9 mm Hg in SPRINT versus 8.8 and 8.2 mm Hg in ACCORD; P<0.001). The relationship
between achieved SBP and outcomes was consistent across trials except for stroke and all-cause death. Higher visit-to-visit
variability was more common in SPRINT but without treatment-effect heterogeneity.
Conclusions-—SPRINT and ACCORD had different degrees of separation in achieved SBP between treatment groups, even as they
had similar mean differences. The greater between-group overlap of achieved SBP may have contributed to the discordant trial
results. ( J Am Heart Assoc. 2017;6:e007509. DOI: 10.1161/JAHA.117.007509.)
Key Words: ACCORD (Action to Control Cardiovascular Risk in Diabetes) • outcome • systolic blood pressure • SPRINT (Systolic
Blood Pressure Intervention Trial)

C

linicians and patients face uncertainty about the
optimal systolic blood pressure (SBP) goals to reduce
adverse cardiovascular outcomes.1 In recent years, 2 major
studies, SPRINT (Systolic Blood Pressure Intervention Trial)2
and the ACCORD (Action to Control Cardiovascular Risk in
Diabetes) blood pressure trial,3 tested the cardiovascular
beneﬁt of intensive (<120 mm Hg) versus standard
(<140 mm Hg) SBP control. Although both trials used

similar interventions and achieved similar average SBP, they
had different results. SPRINT, which enrolled people without
diabetes mellitus, found a beneﬁt with an intensive SBP
target, but ACCORD, which enrolled people with diabetes
mellitus, did not. Several theories have attributed the
discordant results to differences in outcome deﬁnitions,
sample sizes, trial participant characteristics, or blood
pressure measurement technique.1,4,5
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Clinical Perspective
What Is New?
• Our study shows a difference in the distributions of systolic
blood pressure (SBP) achieved in SPRINT (Systolic Blood
Pressure Intervention Trial) and ACCORD (Action to Control
Cardiovascular Risk in Diabetes): ACCORD had less separation of the SBP between intensive and standard treatment
groups compared with SPRINT, even though they achieved
similar average SBP levels.
• Meanwhile, the relationship of SBP with cardiovascular
outcomes was largely similar in both trials.
• These results are consistent with a theory that the less
between-group separation in ACCORD may help explain
discrepancy between the results in SPRINT and ACCORD.

What Are the Clinical Implications?
Downloaded from http://jaha.ahajournals.org/ by guest on December 1, 2017

• ACCORD may have demonstrated a smaller cardiovascular
beneﬁt than SPRINT because ACCORD had poorer separation between treatment groups compared with SPRINT.
• Given this ﬁnding, ACCORD may be seen as consistent with
SPRINT’s ﬁnding that an SBP goal of 120 mm Hg is
associated with cardiovascular beneﬁt compared with
140 mm Hg.

In this study, we explore an alternative theory: The
different outcome results in SPRINT and ACCORD were
caused by differences in the SBP responses of the participants. Previous research has demonstrated marked variations
of SBP response among participants within a treatment
group.6 Although average SBPs appeared similar between
SPRINT and ACCORD, we sought to understand whether there
were unappreciated variations in SBP response. To address
the proposed theory, we tested 3 hypotheses. First, we
determined whether there were differences between trials in
the distributions of achieved SBP, especially in the separation
of their respective treatment groups. Second, we investigated
whether the achieved SBP had different relationships with
cardiovascular outcomes between trials, independent of
treatment strategy. Third, we sought to determine whether
there were differences between trials in the distribution of
visit-to-visit variability, also known to be prognostic,7,8 and
whether visit-to-visit variability was associated with treatment-effect heterogeneity.

Methods
Data Source and Study Design
Data are available, on request, from the National Institutes of
Health. The SPRINT and ACCORD trials have been described
previously.2,3,9,10 Brieﬂy, SPRINT was a randomized
DOI: 10.1161/JAHA.117.007509

Figure 1. Flowchart of study participants for analysis. A, Data
points for systolic blood pressure (SBP) response assessment and
the association of SBP response and cardiovascular outcomes. B,
Exclusion criteria applied to obtain the study sample. ACCORD
indicates Action to Control Cardiovascular Risk in Diabetes;
SPRINT, Systolic Blood Pressure Intervention Trial.

multicenter trial to determine whether an intensive control
strategy (SBP <120 mm Hg) was superior to a standard
strategy (SBP <140 mm Hg) among 9361 nondiabetic participants aged ≥50 years at increased cardiovascular risk. The
ACCORD blood pressure trial tested the intensive versus
standard SBP control strategies among 4733 participants with
diabetes mellitus at high cardiovascular risk. The median
follow-up durations of SPRINT and ACCORD were 3.26 and
4.7 years, respectively.
We used the SBP measurements during each trial’s ﬁrst
year after randomization to assess the SBP responses to
intensive or standard treatment (Figure 1A). We studied 5
outcomes: the primary outcome deﬁned in SPRINT, the
primary outcome deﬁned in ACCORD, heart failure, stroke,
and all-cause death. Participants were followed from 1 year
until the ﬁrst occurrence of an outcome event or the end of
Journal of the American Heart Association
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SBP Measurements and Evaluation of SBP
Response Distributions
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To evaluate the SBP response distributions, we used the SBP
measurements from all visits during the ﬁrst year of each trial.
We used 1 year of data to allow adequate time for participants assigned to either intensive or standard strategies to
reach their SBP goals and to increase the precision of the
estimation of visit-to-visit variability. A total of 7 visits
(baseline and 1, 2, 3, 6, 9, and 12 months) for both treatment
groups in SPRINT and 9 visits (baseline and 1, 2, 3, 4, 6, 8, 10,
and 12 months) for the intensive group and 5 visits (baseline
and 1, 4, 8, and 12 months) for the standard group in
ACCORD were included.
We used growth mixture modeling11 to estimate the
distribution of achieved SBP and visit-to-visit variability for
each treatment group of each trial. Because of the larger
initial drop of SBP in the intensive group, a conventional visitto-visit variability metric based on standard deviations tends
to produce higher variability for intensive-group participants
than for participants in the standard group and thus is not
applicable. Growth mixture modeling can account for the SBP
trends and estimate the intraindividual variance across visits
(visit-to-visit variability) based on the ﬂuctuations around the
SBP trends. In addition, growth mixture modeling captures the
interindividual variance of SBP, facilitating estimation for the
distribution of achieved SBP. More speciﬁcally, we derived 4
growth mixture models, each for participants from the same
treatment group of the same trial. For each model, we used a
piecewise linear function of time to model the SBP trend,
mixture components to model distinct classes (strata) of visitto-visit variability, and mixed effects to model the interindividual variance of achieved SBP. Finally, to compare trials in
the distribution of visit-to-visit variability, we restricted the
mixture components to be the same across 4 models. The
number of visit-to-visit variability classes was determined
based on Bayesian information criteria and the restriction that
the percentage of participants in each class should not be
<5%. Participants were assigned to the visit-to-visit variability
class corresponding to their highest posterior probability.
Furthermore, we calculated the estimated achieved SBP at
1 year for all participants from the models using the empirical
Bayes method,12 including those with missing SBP measurement at 1 year.
DOI: 10.1161/JAHA.117.007509

Clinical Outcomes
Clinical outcomes included the primary outcome of SPRINT,
the primary outcome of ACCORD, heart failure, stroke, and allcause death, as deﬁned in their respective trials.2,3 A
combination of secondary outcomes from ACCORD was used
to construct a composite outcome comparable to SPRINT’s
primary outcome: nonfatal myocardial infarction, nonfatal
stroke, congestive heart failure, and death from cardiovascular causes. A combination of secondary outcomes from
SPRINT was used to construct a composite outcome comparable to ACCORD’s primary outcome: myocardial infarction,
stroke, and death from cardiovascular causes. We included
outcomes occurring from 1 year after randomization through
the end of follow-up for each trial.

Statistical Analyses
We ﬁrst evaluated the distributions of achieved SBP and visitto-visit variability for the intensive and standard treatment
groups in SPRINT and ACCORD by modeling the SBP
responses during the ﬁrst year via growth mixture modeling.
We used likelihood ratio tests to assess whether there were
signiﬁcant differences in the mean and variance of achieved
SBP at 1 year between SPRINT and ACCORD in their
respective treatment groups. The degree of separation
between treatment groups in the distribution of achieved
SBP was also assessed by the overlap coefﬁcient,13 which
quantiﬁes the overlap area between 2 probability density
functions.
We next used the achieved SBP of individual participants at
1 year estimated from the growth mixture models to examine
the association of achieved SBP with outcomes. Each
participant was also assigned to a visit-to-visit variability
class according to the estimated growth mixture models.
First, for all participants of each trial, regardless of treatment
assignment, we assessed differences in characteristics at
baseline and during the ﬁrst year after randomization across
tertiles of achieved SBP, using t tests or Wilcoxon–Mann–
Whitney tests for continuous variables and v2 tests for
categorical variables. The tertiles were determined using the
pooled participants from both trials. Next, Cox proportional
hazards regression models were used to calculate outcome
risks associated with increasing tertiles of achieved SBP
(modeling tertile as an ordinal variable) without and with
adjustment for baseline demographics and blood pressure,
past medical history, visit adherence, and visit-to-visit
variability. Differences in trends between trials were assessed
by comparing Cox hazard models derived from pooled
participants of both trials with models derived separately
from participants of SPRINT or ACCORD using Wald tests. To
account for different baseline risks of the 2 trial populations,
stratiﬁed Cox hazard models were used for the pooled
Journal of the American Heart Association

3

ORIGINAL RESEARCH

follow-up for each trial. We excluded participants who had
outcome events during the ﬁrst year (n=221 for SPRINT and
n=117 for ACCORD) and those with no follow-up SBP (n=113
for SPRINT and n=41 for ACCORD; Figure 1B). All participants
provided written informed consent for participation in SPRINT
and ACCORD. Our analysis was approved by the institutional
review board at Yale University.
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modeling was performed using R package OpenMx (version
2.5.2).16 Multiple imputation was performed using R
package mice (version 2.25),17 and a continuous hazard
ratio was calculated using R package rms (version 5.1-1).18
All P values reported are nominal, and P<0.1 was
considered signiﬁcant for tests of trial heterogeneity and
interactions.19,20

Results
Modeling SBP Responses
Of the 9361 SPRINT participants and 4733 ACCORD blood
pressure trial participants, 9027 (96.4%) from SPRINT and
4575 (96.7%) from ACCORD were included in our analyses
(Figure 1B). When modeling the SBP responses for these
participants using growth mixture models, based on Bayesian
information criteria and the percentage of participants in each
class, the 3-class visit-to-visit variability models best ﬁt the
data (Table S1).
Figure 2 shows, for SPRINT (Figure 2A) and ACCORD
(Figure 2B), the estimated mean SBP trends (solid lines) and
individual SBP measurements over time (gray circle markers)
associated with each visit-to-visit variability class in the
intensive (top row) and standard treatment groups (bottom
row). Three classes of visit-to-visit variability with increasing

Figure 2. Results of modeling systolic blood pressure (SBP) response in (A) SPRINT (Systolic Blood Pressure Intervention Trial) and (B)
ACCORD (Action to Control Cardiovascular Risk in Diabetes), by visit-to-visit variability classes. Solid lines represent the estimated mean SBP
trends. gray circle markers represent individual SBP measurements over time. Red dashed lines are reference lines of 120 and 140 mm Hg.
Classes 1, 2, and 3 have increasing values of visit-to-visit variability of 5.7, 10.8, and 17.9 mm Hg, respectively.
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participants. In addition, we tested the interaction of treatment with achieved SBP modeled as a continuous variable for
the middle tertile, which contained considerable percentages
of participants from both treatment groups. Furthermore, we
assessed adjusted hazard ratios of outcomes associated with
the achieved SBP, modeled as a continuous variable, using
restricted cubic splines. The proportionality assumption of the
Cox hazard model was tested by examining the Schoenfeld
residuals.14
Finally, we determined whether there were signiﬁcant
differences in the distributions of visit-to-visit variability
between SPRINT and ACCORD by comparing percentages of
participants in the classes of visit-to-visit variability identiﬁed
from the growth mixture models using v2 tests. To evaluate
the impact of the visit-to-visit variability on treatment effect in
outcomes, we calculated the adjusted hazard ratios for
outcomes associated with intensive compared with standard
treatment using Cox proportional hazards regression models.
We also tested the interaction of treatment with visit-to-visit
variability class.
Missing baseline characteristics were imputed with 10
data sets using chained equations via multiple imputation.15
For sensitivity analyses, we repeated the evaluation of SBP
response distributions and calculation of Cox proportional
hazard ratios for participants without missing follow-up SBP
measurements during the ﬁrst year. Growth mixture
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Framingham Risk Scores, urine albumin/creatinine ratios, and
baseline blood pressure.

Distributions of Achieved SBP in SPRINT and
ACCORD

Association of Achieved SBP With Outcomes in
SPRINT and ACCORD

The distributions of achieved SBP at 1 year in the intensive
and standard treatment groups were signiﬁcantly different
between SPRINT and ACCORD (Figure 3). First, SPRINT and
ACCORD had small but statistically signiﬁcant differences in
the mean achieved SBP at 1 year in the 2 treatment groups
(120.2 and 135.9 mm Hg in SPRINT versus 120.0 and
134.2 mm Hg in ACCORD; P<0.001), resulting in a slightly
smaller between-group mean difference in ACCORD
(14.2 mm Hg) than in SPRINT (15.7 mm Hg). Second,
ACCORD had larger standard deviations of achieved SBPs at
1 year in the intensive and standard groups (8.8 and
8.2 mm Hg, respectively, in ACCORD versus 6.7 and
5.9 mm Hg, respectively, in SPRINT; P<0.001). The overlap
area between intensive and standard groups in the distribution of achieved SBP is 20.2% for SPRINT and 40.3% for
ACCORD.
Characteristics of participants by tertile of their estimated
achieved SBP at 1 year are presented in Table 1. ACCORD
had more participants from the intensive group in the highest
tertile of achieved SBP compared with SPRINT (8.1% versus
1.2%). For both trials, participants with higher achieved SBP
were older, had worse kidney function, and had higher

We found no signiﬁcant differences between SPRINT and
ACCORD in the relationship of tertiles of estimated SBP
achieved at 1 year and each outcome in unadjusted or adjusted
models, except for stroke and all-cause death (Table 2).
Incidence of the primary outcome of SPRINT, the primary
outcome of ACCORD, and heart failure were all progressively
higher at higher tertiles of achieved SBP; furthermore, incidence
of stroke was higher at higher achieved SBP in ACCORD but not
in SPRINT, whereas incidence of all-cause death was higher at
higher achieved SBP in SPRINT but not in ACCORD. After
multivariable adjustment, the hazard ratio comparing the
pooled participants from both trials in the highest versus
lowest tertile of achieved SBP was 1.50 (95% conﬁdence
interval, 1.24–1.81) for the primary outcome of SPRINT, 1.35
(95% conﬁdence interval, 1.09–1.68) for the primary outcome
of ACCORD, and 1.97 (95% conﬁdence interval, 1.39–2.80) for
heart failure. No violation of the proportionality assumption was
found in the Cox hazard models. In addition, for all outcomes, no
interaction of treatment with achieved SBP was found for
participants in the middle tertile.
The estimated achieved SBP at 1 year modeled as a
continuous variable showed a linear relationship with risks of

Figure 3. Distribution of achieved systolic blood pressure (SBP) at 1 year in intensive and standard treatment groups of (A) SPRINT (Systolic
Blood Pressure Intervention Trial) and (B) ACCORD (Action to Control Cardiovascular Risk in Diabetes) estimated from modeling the SBP
response during the ﬁrst year. Error bars represent 1 SD from the mean SBP.
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values were identiﬁed (referred to as classes 1, 2, and 3), with
estimated values of 5.7, 10.8, and 17.9 mm Hg.
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Table 1. Participant Characteristics by Estimated SBP Achieved at 1 Year
SPRINT

ACCORD

Tertile of Achieved SBP

Characteristic

<122 mm Hg
(n=2966)

122–
134 mm Hg
(n=2856)

>134 mm Hg
(n=3205)

P Value
for
Trend

<122 mm Hg
(n=1568)

122–
134 mm Hg
(n=1678)

>134 mm Hg
(n=1329)

P Value for
Trend

Intensive group, n (%)

2963 (99.9)

1526 (53.4)

37 (1.2)

<0.001

1504 (95.9)

675 (40.2)

108 (8.1)

<0.001

Age, y

66.99.1

68.49.4

68.19.5

<0.001

62.06.6

62.86.5

63.36.8

<0.001

White, n (%)

1698 (57.2)

1704 (60.0)

1815 (56.6)

0.859

995 (63.5)

1006 (60.0)

683 (51.4)

<0.001

1052 (35.5)

1000 (35.0)

1160 (36.2)

0.541

756 (48.2)

796 (47.4)

627 (47.2)

0.572

Baseline characteristics

Female, n (%)

30.35.8

29.75.9

29.65.5

<0.001

32.25.6

32.35.4

31.95.4

0.082

Framingham Risk Score, %

22.911.8

25.012.4

26.012.8

<0.001

32.216.1

34.916.9

38.416.6

<0.001

Estimated GFR, mL/min/
1.73 m2

73.020.3

71.320.9

71.320.4

0.002

91.722.8

90.522.9

89.823.7

0.029

Total

188.841.6

190.141.5

191.640.3

0.007

192.242.3

191.041.6

192.042.0

0.855

High-density lipoprotein

52.013.5

53.615.1

53.114.8

0.002

46.212.9

45.613.0

46.712.9

0.425

Triglycerides, mg/dL

126.184.5

124.184.3

127.1100.3

0.630

185.4131.0

188.8131.2

176.0122.1

0.065

Glucose, mg/dL

99.213.7

98.414.0

98.813.0

0.268

173.453.8

175.654.8

171.855.6

0.473

Ratio of urinary albumin
(mg) to creatinine (g)

33.7164.5

43.7161.6

44.4170.3

0.012

54.0181.2

74.7219.8

127.3330.6

<0.001

Aspirin use, n (%)

1539 (51.9)

1469 (51.4)

1590 (49.6)

0.074

844 (53.8)

906 (54.0)

649 (48.8)

0.009

Statin use, n (%)

1281 (43.2)

1255 (43.9)

1385 (43.2)

0.925

1044 (66.6)

1095 (65.3)

845 (63.6)

0.097

Antihypertensive medication
use, n (%)

2690 (90.7)

2584 (90.5)

2897 (90.4)

0.685

1358 (86.6)

1454 (86.7)

1201 (90.4)

0.003

Smoking, n (%)

418 (14.1)

367 (12.9)

400 (12.5)

0.063

190 (12.1)

191 (11.4)

147 (11.1)

0.369

Cardiovascular disease,
n (%)

602 (20.3)

584 (20.4)

594 (18.5)

0.078

538 (34.3)

533 (31.8)

436 (32.8)

0.357

Body mass index, kg/m

2
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Cholesterol, mg/dL

Blood pressure, mm Hg
Systolic

135.814.1

139.716.3

143.215.4

<0.001

134.014.3

137.914.8

146.014.1

0.001

Diastolic

77.911.1

77.512.2

79.112.2

<0.001

74.69.8

75.69.9

77.59.8

<0.001

Characteristics 0–1 year after randomization
No. antihypertensive
medications

2.50.9

2.21.1

2.00.9

<0.001

2.61.0

2.51.2

2.61.1

0.138

No. changes in no.
antihypertensive medications

0.91.0

1.41.2

1.11.1

<0.001

1.71.3

1.71.4

1.51.3

0.007

Visit adherence, n (%)*

2575 (86.8)

2314 (81.0)

2692 (84.0)

0.004

1116 (71.2)

1304 (77.7)

1141 (85.9)

<0.001

Values are meanSD except as noted. ACCORD indicates Action to Control Cardiovascular Risk in Diabetes; GFR, glomerular ﬁltration rate; SBP, systolic blood pressure; SPRINT, Systolic
Blood Pressure Intervention Trial.
*Visit adherence was deﬁned as not missing any visit during the ﬁrst year after randomization. SPRINT required the intensive and standard groups to have visits at 1, 3, 6, 9, and 12 mo.
ACCORD required the intensive group to have visits at 1, 2, 3, 4, 6, 8, 10, and 12 mo and the standard group to have visits at 1, 4, 8, and 12 mo.

the primary outcomes of SPRINT and ACCORD and heart failure
(Figure S1). For stroke, a gradual increase in risk for higher
achieved SBP was found in ACCORD but not in SPRINT. For allcause death, risk in SPRINT increased progressively with
achieved SBP until 130 mm Hg, whereas the risk in ACCORD
did not change much over the range of achieved SBP.
DOI: 10.1161/JAHA.117.007509

Distribution of Visit-to-Visit Variability and
Association With Treatment Effect Heterogeneity
SPRINT and ACCORD also had signiﬁcant differences in
percentages of participants from intensive and standard
treatment groups in the 3 classes of visit-to-visit variability
Journal of the American Heart Association
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Table 2. Post–1-Year Outcomes Associated With Estimated SBP Achieved at 1 Year
Tertile of Achieved SBP
Variable

Participants

<122 mm Hg

122–134 mm Hg

>134 mm Hg

P Value for Trend

P Value for Trial
Heterogeneity of HRs

SPRINT primary outcome (myocardial infarction, acute coronary syndrome, stroke, heart failure, or death from cardiovascular causes)
No. events (%)

Unadjusted HR (95% CI)

SPRINT

98 (3.3)

126 (4.4)

156 (4.9)

0.002

ACCORD

115 (7.3)

172 (10.3)

154 (11.6)

<0.001

All*

1.00

1.41 (1.18–1.68)

1.55 (1.30–1.84)

<0.001

SPRINT

Adjusted HR (95% CI)

‡

†

1.00

1.40 (1.07–1.82)

1.52 (1.18–1.95)

0.001

ACCORD†

1.00

1.42 (1.12–1.79)

1.57 (1.24–2.00)

<0.001

All*

1.00

1.31 (1.09–1.56)

1.50 (1.24–1.81)

<0.001

1.00

1.27 (0.97–1.67)

1.50 (1.15–1.95)

0.003

1.00

1.33 (1.05–1.69)

1.49 (1.15–1.92)

0.002

SPRINT

†

ACCORD

†

0.977

0.951

ACCORD primary outcome (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes)
No. events (%)
Downloaded from http://jaha.ahajournals.org/ by guest on December 1, 2017

Unadjusted HR (95% CI)

SPRINT

67 (2.3)

94 (3.3)

ACCORD

97 (6.2)

135 (8.0)

120 (9.0)

0.004

All*

1.00

1.39 (1.14–1.70)

1.46 (1.19–1.78)

<0.001

1.00

1.52 (1.11–2.08)

1.49 (1.09–2.02)

0.015

1.00

1.31 (1.01–1.70)

1.44 (1.10–1.88)

0.007

1.00

1.27 (1.03–1.56)

1.35 (1.09–1.68)

0.008

1.00

1.36 (0.99–1.88)

1.41 (1.03–1.93)

0.042

1.00

1.20 (0.92–1.57)

1.31 (0.98–1.74)

0.065

SPRINT

21 (0.7)

36 (1.3)

55 (1.7)

<0.001

ACCORD

36 (2.3)

54 (3.2)

49 (3.7)

0.028

SPRINT

†

ACCORD
Adjusted HR (95% CI)‡

†

All*
SPRINT

†

ACCORD

†

105 (3.3)

0.020

0.726

0.832

Heart failure
No. events (%)

Unadjusted HR (95% CI)

Adjusted HR (95% CI)

‡

All*

1.00

1.58 (1.13–2.20)

1.93 (1.40–2.67)

<0.001

SPRINT†

1.00

1.86 (1.09–3.19)

2.51 (1.52–4.15)

<0.001

ACCORD†

1.00

1.41 (0.92–2.14)

1.57 (1.02–2.42)

0.039

All*

1.00

1.45 (1.03–2.05)

1.97 (1.39–2.80)

<0.001

SPRINT†

1.00

1.70 (0.98–2.95)

2.72 (1.61–4.58)

<0.001

ACCORD†

1.00

1.31 (0.85–2.02)

1.51 (0.95–2.38)

0.080

SPRINT

20 (0.7)

36 (1.3)

33 (1.0)

0.170

ACCORD

11 (0.7)

32 (1.9)

36 (2.7)

<0.001

All*

1.00

2.21 (1.44–3.37)

2.30 (1.51–3.52)

<0.001

0.383

0.209

Stroke
No. events (%)

Unadjusted HR (95% CI)

SPRINT

Adjusted HR (95% CI)

‡

†

1.00

1.95 (1.13–3.36)

1.56 (0.90–2.72)

0.150

ACCORD†

1.00

2.71 (1.37–5.39)

3.78 (1.92–7.42)

<0.001

All*

1.00

2.00 (1.29–3.08)

2.11 (1.34–3.30)

0.002

1.00

1.72 (0.99–3.00)

1.44 (0.81–2.57)

0.277

1.00

2.51 (1.26–5.01)

3.45 (1.71–6.95)

<0.001

SPRINT

58 (2.0)

106 (3.7)

111 (3.5)

<0.001

ACCORD

73 (4.7)

90 (5.4)

74 (5.6)

0.261

All*

1.00

1.49 (1.20–1.86)

1.45 (1.16–1.81)

0.002

1.00

1.98 (1.44–2.73)

1.82 (1.33–2.51)

<0.001

SPRINT

†

ACCORD

†

0.092

0.120

All-cause death
No. events (%)

Unadjusted HR (95% CI)

SPRINT

†

0.035

Continued
DOI: 10.1161/JAHA.117.007509
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Table 2. Continued
Tertile of Achieved SBP
Variable

Adjusted HR (95% CI)

‡

Participants

<122 mm Hg

122–134 mm Hg

>134 mm Hg

P Value for Trend

ACCORD†

1.00

1.12 (0.83–1.53)

1.14 (0.82–1.57)

0.426

All*

1.00

1.36 (1.08–1.71)

1.38 (1.09–1.76)

0.011

SPRINT†

1.00

1.72 (1.24–2.39)

1.70 (1.22–2.37)

0.003

ACCORD†

1.00

1.08 (0.79–1.48)

1.11 (0.79–1.57)

0.530

P Value for Trial
Heterogeneity of HRs

0.098

ACCORD indicates Action to Control Cardiovascular Risk in Diabetes; CI, conﬁdence interval; GFR, glomerular ﬁltration rate; HR, hazard ratio; SBP, systolic blood pressure; SPRINT, Systolic
Blood Pressure Intervention Trial.
*Modeling of the pooled participants from SPRINT and ACCORD, with stratiﬁed baseline hazard functions by trial.
†
Modeling separately of the participants from SPRINT or ACCORD.
‡
Adjusted for age, race, sex, Framingham Risk Score, baseline SBP and diastolic blood pressure, use of antihypertensive medication before randomization, smoking status, aspirin use,
estimated GFR, history of clinical/subclinical cardiovascular disease, total cholesterol, high-density lipoprotein, triglycerides, glucose, urine albumin/creatinine ratio, body mass index,
statin use, number of antihypertensive medications used, visit adherence, and visit-to-visit variability class.
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(Figure S2). For the intensive group, SPRINT had 19.9%,
70.6%, and 9.5% and ACCORD had 20.0%, 73.8%, and 6.2% of
participants in the 3 classes of increasing visit-to-visit
variability. For the standard group, SPRINT had 16.5%,
72.3%, and 11.2% and ACCORD had 16.1%, 80.0%, and 3.9%
in these classes. Tests for differences between trials in
percentages for treatment groups combined and for each
treatment group separately had P<0.001.
For both trials, participants with higher visit-to-visit
variability were older, less often white, and more often
female. They also had worse kidney function, higher Framingham Risk Scores, urine albumin/creatinine ratios, and
baseline SBP and were more likely to be on antihypertensive
medication before randomization (Table S2). During the ﬁrst
year, participants in both trials with higher visit-to-visit
variability used more medications, had more changes in the
number of medications, and were more likely to have low visit
adherence.
Incidence of each outcome was progressively higher for
participants in classes of higher visit-to-visit variability
(Table S3). The relationships of visit-to-visit variability classes
and outcomes were consistent between trials except for the
primary outcomes of SPRINT and ACCORD; the adjusted
hazard ratios of higher versus lower visit-to-visit variability in
ACCORD were higher than those in SPRINT for the 2
composite outcomes.
Finally, with 1 exception, the associations of intensive
versus standard treatment with the risks of all outcomes were
consistent across classes of visit-to-visit variability for both
trials (Figure S3).
In sensitivity analyses, similar results in the association of
achieved SBP and visit-to-visit variability with outcomes were
found for participants without missing SBP measurement
during the ﬁrst year, except that there was no signiﬁcant
difference between SPRINT and ACCORD in the relationship of
achieved SBP with stroke (Tables S4 and S5).
DOI: 10.1161/JAHA.117.007509

Discussion
Our principal ﬁndings are consistent with a hypothesis that a
smaller difference in the separation of achieved SBP between
the intensive and standard groups in ACCORD compared with
SPRINT may have contributed to the discordant results
between the trials. Although the average SBP levels achieved
in both trials were quite similar, there was much better
separation of the SBP between treatment groups in SPRINT
compared with ACCORD. Meanwhile, the relationship of
achieved SBP with outcomes was similar regardless of
treatment group in both trials, except for stroke and death.
Finally, although there was a difference in percentages of
participants in different visit-to-visit variability classes, it did
not appear to modify the risk relationship between the 2
treatment groups in both trials. There were some differences
in the participant characteristics of SPRINT and ACCORD; for
example, ACCORD included exclusively adults with diabetes
mellitus, whereas SPRINT excluded people with diabetes
mellitus. It is important to note that we tested whether SBP
had a similar modifying effect on outcomes for both SPRINT
and ACCORD and found that the relationship of SBP with
outcomes was largely similar despite some differences in
participant characteristics, suggesting comparability of SBP
response and cardiovascular risk in the 2 trials.
Some experts have commented that ACCORD lacked
power to detect meaningful differences in outcomes because
of the event rates being lower than expected.4 Our results
show that lower SBP reduced risks of cardiovascular
outcomes for both trials, but ACCORD had a higher percentage of standard-group participants with lower achieved SBP
compared with SPRINT, and that may have contributed to the
low event rate of the standard group. Furthermore, the large
overlap of achieved SBP between the treatment groups in
ACCORD may have diminished the contrast between the
groups and resulted in less power to detect a difference in
Journal of the American Heart Association
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standard group, which may have diminished the beneﬁt for the
intensive group seen in the remaining participants. However,
the exclusion pattern in the trials was similar and should not
have had an important effect on the comparison of the trials to
each other. Last, the analysis was based on achieved SBP
instead of the intent-to-treat assignment groups, and this may
have introduced bias26; however, we adjusted for all available
participant characteristics and visit adherence, and no significant interaction with treatment was found. Our ﬁndings do not
likely fully explain the discordant results of SPRINT and
ACCORD. A recent meta-analysis shows that patients with
diabetes mellitus may have a signiﬁcant but smaller relative
risk reduction in cardiovascular outcomes compared with
patients without diabetes mellitus for a given magnitude of
blood pressure lowering.24 A simulation analysis suggests that
differences in the number of drugs and diastolic blood
pressure between the trials could have contributed to the
differences.27
In conclusion, this study provides evidence that may help
explain the different results in SPRINT and ACCORD. The
principal discovery is that although the trials had similar
average SBP levels achieved in the 2 treatment groups at
1 year, they had different degrees of separation between the
intensive and standard treatment groups. There was also
other evidence of differences in SBP response, as indicated by
the visit-to-visit variability differences in the trials, although no
evidence of its contribution to different trial results was found.
The ﬁndings suggest that the greater overlap in SBP between
intensive and standard groups in ACCORD may have diminished the contrast between the groups and been the reason
for the smaller beneﬁt estimate and the lack of statistical
signiﬁcance. If true, then ACCORD should be viewed as more
consistent with the thesis that a more intensive SBP control
strategy is better—as shown in SPRINT.
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outcomes. What is important is that assessing the average
SBP values in the trials was not sufﬁcient to appreciate the
differences in the separation of the treatment groups.
Our study cannot determine the cause for the differences
in the distribution of achieved SBP between the trials. An
explanation is that the implementation of the intervention was
simply more effective in SPRINT. In addition, SPRINT was
singularly a blood pressure trial, whereas ACCORD had 3
components including the diabetes trial,10 a lipid trial, and a
blood pressure trial, which may have had some impact on SBP
responses. It is possible that the difference in the SBP
distribution was also related to underlying diabetes mellitus,
perhaps because controlling blood pressure in patients with
diabetes mellitus may be more difﬁcult and slower.21,22
Our ﬁndings of the relationship between SBP and cardiovascular outcomes are consistent with the ﬁndings of 2 recent
comprehensive meta-analyses of blood pressure lowering.23,24 Both meta-analyses included only randomized trials
of blood pressure lowering, and both concluded that lower
SBP—ideally to <130 mm Hg—was associated with a reduction in the risk of cardiovascular outcomes. One meta-analysis
concluded that the lowest risk of cardiovascular outcomes
and mortality was between 120 and 124 mm Hg,23 similar to
the 120 mm Hg target for the intensive arms of SPRINT and
ACCORD. Moreover, the randomized controlled trial with the
most similar intensive SBP target to SPRINT and ACCORD, the
SPS-3 (Secondary Prevention of Small Subcortical Strokes)
trial with a goal of <130 mm Hg in patients with recent
lacunar stroke compared with a standard goal of 130 to
149 mm Hg, found that treatment reduced the point estimates of multiple cardiovascular outcomes, although the
results were not statistically signiﬁcant.25
Our study has some limitations. First, this study is a
secondary analysis of existing data and was undertaken to
explore explanations for the differences in the trials. Although
we included all available covariates at baseline and during the
ﬁrst year of the trials to minimize the effects of confounding,
the possibility of residual confounding and unmeasured
confounders cannot be eliminated. Second, no information is
currently available about the drugs used in SPRINT, and so we
could not explore differences in speciﬁc treatment strategies.
Third, there were differences in follow-up duration between
SPRINT and ACCORD. Although we found no evidence of the
relationship between SBP and outcomes changing over time
for both trials, we cannot rule out the possibility that SPRINT
might have shown a time-varying relationship if it had not been
stopped early. Fourth, we excluded participants with cardiovascular events during the ﬁrst year in each trial, and that
reduced the number of events available for analysis, although
we still found a signiﬁcant increase in risk with higher achieved
SBP. Furthermore, participants with more comorbidities and
higher nonadherence were preferentially excluded from the
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SUPPLEMENTAL MATERIAL

Table S1. Model selection.

Model

-2Loglikelihood

BIC*
1

1 class
2 classes
3 classes
4 classes

485795
483155
482801
482731

486185
483622
483313
483288

61.6
18.1
3.4

* BIC denotes the Bayesian Information Criteria.

Proportion in class (%)
2
3
4
38.4
73.3
47.4

8.6
46.4

2.8
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Table S2. Participant characteristics by visit-to-visit variability of systolic blood pressure (SBP).*
SPRINT

ACCORD
Class of visit-to-visit variability

Characteristic

5.7 mmHg
(N=1642)
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Intensive group—no.
899 (54.8)
(%)
Baseline characteristics
Age—yr
66.6±8.9
White—no. (%)
952 (58.0)
Female—no. (%)
428 (26.1)
Body-mass index—
30.1±5.4
kg/m2
Framingham Risk
23.9±11.4
Score—%
Estimated GFR—
74.3±18.9
ml/min/1.73 m2
Cholesterol—mg/dl
Total
189.4±41.8
High-density lipoprotein
51.2±13.4
Triglycerides—mg/dl
127.4±83.1
Glucose—mg/dl
99.4±12.5
Ratio of urinary albumin
32.2±151.0
(mg) to creatinine (g)
Aspirin use—no. (%)
821 (50.0)
Statin use—no. (%)
717 (43.7)
Antihypertensive
1461 (89.0)
medication use—no. (%)
Smoking—no. (%)
182 (11.1)
Cardiovascular
269 (16.4)
disease—no. (%)
Blood pressure—mmHg
Systolic
136.3±10.6
Diastolic
77.9 (10.3)
Characteristics 0-1 year post-randomization
No. antihypertensive
2.0±1.0
medications
No. changes in no.
antihypertensive
0.7±0.9
medications
Visit adherence—no.
89.9
(%)†

10.8 mmHg
(N=6449)

17.9 mmHg
(N=936)

p value
for trend

5.7 mmHg
(N=825)

10.8 mmHg
(N=3519)

17.9 mmHg
(N=231)

p value
for trend

3196 (49.6)

431 (46.0)

<0.001

457 (55.4)

1688 (48.0)

142 (61.5)

0.248

67.9±9.3
3784 (58.7)
2331 (36.1)

69.4±10.0
481 (51.4)
453 (48.4)

<0.001
0.011
<0.001

61.9±7.1
504 (61.1)
347 (42.1)

62.8±6.5
2068 (58.8)
1701 (48.3)

64.0±6.9
112 (48.5)
131 (56.7)

<0.001
0.005
<0.001

29.9±5.8

29.4±6.2

0.006

31.6±5.6

32.3±5.4

32.3±5.7

0.006

24.6±12.4

26.6±13.9

<0.001

33.3±16.1

35.0±16.7

40.0±18.7

<0.001

71.7±20.5

68.7±22.6

<0.001

91.9±23.4

90.8±22.9

85.1±24.3

0.001

190.2±40.4
53.0±14.5
126.2±94.1
98.8±13.7

191.7±44.1
55.1±15.7
120.3±75.1
97.9±14.5

0.185
<0.001
0.088
0.009

187.5±40.7
45.3±12.5
185.3±130.1
172.3±51.5

192.3±42.2
46.3±13.0
183.7±128.6
174.2±54.9

198.4±41.6
46.1±13.8
181.9±124.2
172.4±63.1

<0.001
0.090
0.690
0.596

40.2±165.1

58.4±179.8

<0.001

52.4±174.8

84.3±246.0

170.6±411.8

<0.001

3317 (51.4)
2810 (43.6)

160 (49.1)
394 (42.1)

0.995
0.574

420 (50.9)
552 (66.9)

1867 (53.1)
2287 (65.0)

112 (48.5)
145 (62.8)

0.930
0.168

5849 (90.7)

861 (92.0)

0.008

711 (86.2)

3087 (87.7)

215 (93.1)

0.015

845 (13.1)

158 (16.9)

<0.001

90 (10.9)

410 (11.7)

28 (12.1)

0.512

1272 (19.7)

239 (25.5)

<0.001

288 (34.9)

1125 (32.0)

94 (40.7)

0.910

139.5±15.1
78.1 (11.7)

146.5±22.2
79.3 (15.0)

<0.001
0.014

136.7±10.7
75.6 (8.9)

139.0±15.7
75.8 (10.1)

146.1±19.3
77.0 (11.1)

<0.001
0.158

2.2±1.0

2.5±1.0

<0.001

2.4±1.0

2.6±1.1

3.3±1.1

<0.001

1.2±1.1

1.8±1.3

<0.001

1.3±1.3

1.7±1.3

2.4±1.4

<0.001

82.9

81.0

<0.001

81.2

77.2

75.3

0.010

* Plus-minus values are means ±SD. GFR denotes glomerular filtration rate.
† Visit adherence was defined as not missing any visit during the first year post-randomization. SPRINT required
the intensive and standard groups to have visits at 1, 3, 6, 9, and 12 months. ACCORD required the intensive group
to have visits at 1, 2, 3, 4, 6, 8,10, and 12 months and the standard group at 1, 4, 8, and 12 months.

Table S3. Post 1-year outcomes associated with visit-to-visit variability classes.
Class of visit-to-visit variability
Variable

Participants
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SPRINT primary outcome
SPRINT
No. events (%)
ACCORD
All*
Unadjusted
Hazard Ratio
SPRINT†
(95% CI)
ACCORD†
All*
Adjusted
Hazard Ratio
SPRINT†
(95% CI)‡
ACCORD†
ACCORD primary outcome
SPRINT
No. events (%)
ACCORD
All*
Unadjusted
Hazard Ratio
SPRINT†
(95% CI)
ACCORD†
All*
Adjusted
Hazard Ratio
SPRINT†
(95% CI)‡
ACCORD†
Heart failure
SPRINT
No. events (%)
ACCORD
All*
Unadjusted
Hazard Ratio
SPRINT†
(95% CI)
ACCORD†
All*
Adjusted
Hazard Ratio
SPRINT†
(95% CI)‡
ACCORD†
Stroke
SPRINT
No. events (%)
ACCORD
All*
Unadjusted
Hazard Ratio
SPRINT†
(95% CI)
ACCORD†
All*
Adjusted
Hazard Ratio
SPRINT†
(95% CI)‡
ACCORD†
All-cause death
SPRINT
No. events (%)
ACCORD
All*
Unadjusted
Hazard Ratio
SPRINT†
(95% CI)
ACCORD†
All*
Adjusted
Hazard Ratio
SPRINT†
(95% CI)‡
ACCORD†

5.7 mmHg

10.8 mmHg

17.9 mmHg

P value
for trend

53 (3.2)
39 (4.7)
1.00
1.00
1.00
1.00
1.00
1.00

267 (4.1)
365 (10.4)
1.75 (1.41-2.18)
1.32 (0.99-1.78)
2.33 (1.68-3.25)
1.54 (1.24-1.92)
1.13 (0.84-1.51)
2.11 (1.51-2.94)

60 (6.4)
37 (16.0)
2.83 (2.12-3.77)
2.09 (1.44-3.02)
4.06 (2.59-6.37)
2.05 (1.53-2.76)
1.51 (1.03-2.19)
2.90 (1.83-4.59)

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
0.034
<0.001

37 (2.3)
31 (3.8)
1.00
1.00
1.00
1.00
1.00
1.00

185 (2.9)
296 (8.4)
1.79 (1.39-2.31)
1.31 (0.92-1.86)
2.37 (1.64-3.43)
1.61 (1.24-2.08)
1.12 (0.79-1.60)
2.19 (1.51-3.18)

44 (4.7)
25 (10.8)
2.76 (1.97-3.87)
2.18 (1.41-3.38)
3.36 (1.99-5.70)
2.04 (1.44-2.88)
1.59 (1.02-2.48)
2.45 (1.43-4.20)

0.001
<0.001
<0.001
<0.001
<0.001
<0.001
0.042
<0.001

12 (0.7)
14 (1.7)
1.00
1.00
1.00
1.00
1.00
1.00

76 (1.2)
108 (3.1)
1.79 (1.18-2.69)
1.67 (0.91-3.07)
1.88 (1.08-3.29)
1.40 (0.93-2.12)
1.29 (0.70-2.38)
1.50 (0.85-2.63)

24 (2.6)
17 (7.4)
4.28 (2.61-7.01)
3.68 (1.84-7.36)
5.09 (2.51-10.34)
2.50 (1.50-4.16)
2.19 (1.08-4.42)
2.89 (1.40-5.97)

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
0.019
0.005

12 (0.7)
8 (1.0)
1.00
1.00
1.00
1.00
1.00
1.00

62 (1.0)
61 (1.7)
1.56 (0.97-2.50)
1.36 (0.73-2.51)
1.86 (0.89-3.89)
1.30 (0.81-2.10)
1.13 (0.60-2.10)
1.57 (0.75-3.29)

15 (1.6)
10 (4.3)
3.13 (1.73-5.66)
2.29 (1.07-4.89)
5.14 (2.03-13.03)
2.05 (1.11-3.79)
1.50 (0.69-3.27)
3.35 (1.29-8.69)

0.045
0.003
<0.001
0.035
0.001
0.024
0.303
0.017

25 (1.5)
34 (4.1)
1.00
1.00
1.00
1.00
1.00
1.00

199 (3.1)
189 (5.4)
1.66 (1.26-2.18)
2.09 (1.38-3.17)
1.34 (0.93-1.94)
1.40 (1.06-1.84)
1.70 (1.12-2.59)
1.17 (0.81-1.69)

51 (5.4)
14 (6.1)
2.69 (1.89-3.84)
3.71 (2.30-5.99)
1.64 (0.88-3.06)
1.86 (1.29-2.68)
2.50 (1.53-4.07)
1.16 (0.61-2.18)

<0.001
0.120
<0.001
<0.001
0.067
<0.001
<0.001
0.486

P value for trial
heterogeneity of
hazard ratio

0.032

0.019

0.072

0.033

0.785

0.859

0.391

0.413

0.116

0.159

CI denotes confidence interval.
*Modeling of the pooled participants from SPRINT and ACCORD, with stratified baseline hazard functions by trial.
†Modeling separately of the participants from SPRINT or ACCORD.
‡Adjusted for age, race, sex, Framingham Risk Score, baseline systolic and diastolic blood pressure, use of
antihypertensive medication before randomization, smoking status, aspirin use, estimated glomerular filtration rate,
history of clinical/subclinical cardiovascular disease, total cholesterol, high-density lipoprotein, triglycerides,
glucose, urine albumin/creatinine ratio, body-mass index, statin use, treatment assignment, number of
antihypertensive medications used, visit adherence, and estimated achieved 1-year systolic blood pressure.

Table S4. Post 1-year outcomes associated with estimated systolic blood pressure (SBP) achieved at 1 year, for
participants without missing SBP measurements during the first year.
Tertile of estimated achieved SBP
Variable

Participants
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SPRINT primary outcome
SPRINT
No. events (%)
ACCORD
All*
Unadjusted
Hazard Ratio
SPRINT†
(95% CI)
ACCORD†
All*
Adjusted
Hazard Ratio
SPRINT†
(95% CI)‡
ACCORD†
ACCORD primary outcome
SPRINT
No. events (%)
ACCORD
All*
Unadjusted
Hazard Ratio
SPRINT†
(95% CI)
ACCORD†
All*
Adjusted
Hazard Ratio
SPRINT†
(95% CI)‡
ACCORD†
Heart failure
SPRINT
No. events (%)
ACCORD
All*
Unadjusted
Hazard Ratio
SPRINT†
(95% CI)
ACCORD†
All*
Adjusted
Hazard Ratio
SPRINT†
(95% CI)‡
ACCORD†
Stroke
SPRINT
No. events (%)
ACCORD
All*
Unadjusted
Hazard Ratio
SPRINT†
(95% CI)
ACCORD†
All*
Adjusted
Hazard Ratio
SPRINT†
(95% CI)‡
ACCORD†
All-cause death
SPRINT
No. events (%)
ACCORD
All*
Unadjusted
Hazard Ratio
SPRINT†
(95% CI)
ACCORD†
All*
Adjusted
Hazard Ratio
SPRINT†
(95% CI)‡
ACCORD†

<122 mmHg

122-134 mmHg

>134 mmHg

P value
for trend

81 (3.1)
74 (6.7)
1.00
1.00
1.00
1.00
1.00
1.00

108 (4.6)
131 (9.7)
1.45 (1.19-1.78)
1.52 (1.14-2.02)
1.41 (1.06-1.88)
1.32 (1.07-1.63)
1.34 (1.00-1.79)
1.31 (0.98-1.76)

122 (4.7)
132 (12.0)
1.61 (1.32-1.96)
1.54 (1.16-2.04)
1.68 (1.26-2.23)
1.53 (1.23-1.90)
1.50 (1.12-2.01)
1.55 (1.15-2.10)

0.005
<0.001
<0.001
0.003
<0.001
<0.001
0.007
0.004

55 (2.1)
64 (5.8)
1.00
1.00
1.00
1.00
1.00
1.00

77 (3.3)
102 (7.6)
1.39 (1.10-1.75)
1.59 (1.12-2.24)
1.29 (0.94-1.77)
1.26 (0.99-1.60)
1.40 (0.99-1.99)
1.16 (0.84-1.59)

85 (3.3)
103 (9.4)
1.52 (1.21-1.92)
1.57 (1.12-2.21)
1.45 (1.06-1.98)
1.42 (1.10-1.82)
1.51 (1.06-2.15)
1.34 (0.96-1.86)

0.014
0.001
<0.001
0.011
0.015
0.007
0.025
0.085

18 (0.7)
20 (1.8)
1.00
1.00
1.00
1.00
1.00
1.00

35 (1.5)
39 (2.9)
1.84 (1.24-2.73)
2.22 (1.26-3.92)
1.56 (0.91-2.68)
1.62 (1.08-2.43)
1.86 (1.04-3.31)
1.43 (0.83-2.48)

39 (1.5)
44 (4.0)
2.16 (1.47-3.18)
2.23 (1.28-3.90)
2.09 (1.23-3.56)
2.10 (1.39-3.17)
2.29 (1.28-4.08)
1.92 (1.10-3.36)

0.014
0.001
<0.001
0.007
0.006
<0.001
0.006
0.020

18 (0.7)
8 (0.7)
1.00
1.00
1.00
1.00
1.00
1.00

29 (1.2)
25 (1.9)
1.98 (1.24-3.17)
1.82 (1.01-3.28)
2.43 (1.10-5.40)
1.82 (1.13-2.96)
1.61 (0.88-2.93)
2.34 (1.04-5.24)

25 (1.0)
28 (2.5)
1.97 (1.23-3.15)
1.41 (0.77-2.59)
3.17 (1.44-6.97)
1.80 (1.09-2.98)
1.34 (0.71-2.52)
2.79 (1.24-6.30)

0.324
<0.001
0.007
0.294
0.004
0.033
0.414
0.017

43 (1.7)
43 (3.9)
1.00
1.00
1.00
1.00
1.00
1.00

84 (3.6)
58 (4.3)
1.58 (1.21-2.07)
2.22 (1.54-3.20)
1.02 (0.69-1.52)
1.38 (1.05-1.82)
1.88 (1.29-2.73)
0.93 (0.62-1.39)

80 (3.1)
53 (4.8)
1.49 (1.13-1.96)
1.91 (1.32-2.77)
1.07 (0.71-1.60)
1.33 (1.00-1.78)
1.75 (1.19-2.57)
0.92 (0.60-1.42)

0.002
0.278
0.006
0.001
0.756
0.078
0.009
0.727

P value for trial
heterogeneity of
hazard ratios

0.681

0.966

0.552

0.725

0.572

0.812

0.208

0.334

0.017

0.028

CI denotes confidence interval.
*Modeling of the pooled participants from SPRINT and ACCORD, with stratified baseline hazard functions by trial.
†Modeling separately of the participants from SPRINT or ACCORD.
‡Adjusted for age, race, sex, Framingham risk score, baseline systolic and diastolic blood pressure, use of
antihypertensive medication before randomization, smoking status, aspirin use, estimated glomerular filtration rate,
history of clinical/subclinical cardiovascular disease, total cholesterol, high-density lipoprotein, triglycerides,
glucose, urine albumin/creatinine ratio, body-mass index, statin use, number of antihypertensive medications used
and visit-to-visit variability class.

Table S5. Post 1-year outcomes associated with visit-to-visit variability, for participants without missing SBP
measurements during the first year.
Class of visit-to-visit variability
Variable

Participants
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SPRINT primary outcome
SPRINT
No. events (%)
ACCORD
All*
Unadjusted
Hazard Ratio
SPRINT†
(95% CI)
ACCORD†
All*
Adjusted
Hazard Ratio
SPRINT†
(95% CI)‡
ACCORD†
ACCORD primary outcome
SPRINT
No. events (%)
ACCORD
All*
Unadjusted
Hazard Ratio
SPRINT†
(95% CI)
ACCORD†
All*
Adjusted
Hazard Ratio
SPRINT†
(95% CI)‡
ACCORD†
Heart failure
SPRINT
No. events (%)
ACCORD
All*
Unadjusted
Hazard Ratio
SPRINT†
(95% CI)
ACCORD†
All*
Adjusted
Hazard Ratio
SPRINT†
(95% CI)‡
ACCORD†
Stroke
SPRINT
No. events (%)
ACCORD
All*
Unadjusted
Hazard Ratio
SPRINT†
(95% CI)
ACCORD†
All*
Adjusted
Hazard Ratio
SPRINT†
(95% CI)‡
ACCORD†
All-cause death
SPRINT
No. events (%)
ACCORD
All*
Unadjusted
Hazard Ratio
SPRINT†
(95% CI)
ACCORD†
All†*
Adjusted
Hazard Ratio
SPRINT†
(95% CI)‡
ACCORD†

5.3 mmHg

10.3mmHg

17.0 mmHg

P value
for trend

40 (3.3)
18 (3.4)
1.00
1.00
1.00
1.00
1.00
1.00

208 (3.8)
273 (9.9)
1.75 (1.33-2.30)
1.17 (0.83-1.64)
3.02 (1.88-4.87)
1.53 (1.16-2.01)
0.97 (0.69-1.37)
2.76 (1.71-4.46)

63 (6.6)
46 (16.1)
3.00 (2.18-4.12)
2.03 (1.37-3.02)
5.23 (3.03-9.02)
2.13 (1.53-2.96)
1.38 (0.92-2.07)
3.86 (2.22-6.72)

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
0.072
<0.001

26 (2.2)
16 (3.0)
1.00
1.00
1.00
1.00
1.00
1.00

147 (2.7)
222 (8.1)
1.84 (1.33-2.53)
1.27 (0.84-1.93)
2.74 (1.65-4.55)
1.64 (1.19-2.26)
1.08 (0.71-1.64)
2.55 (1.53-4.24)

44 (4.6)
31 (10.9)
2.84 (1.95-4.14)
2.17 (1.34-3.53)
3.84 (2.10-7.03)
2.06 (1.39-3.04)
1.52 (0.92-2.48)
2.86 (1.55-5.28)

0.001
<0.001
<0.001
0.001
<0.001
<0.001
0.068
<0.001

10 (0.8)
4 (0.8)
1.00
1.00
1.00
1.00
1.00
1.00

58 (1.1)
78 (2.8)
2.03 (1.17-3.51)
1.31 (0.67-2.56)
3.82 (1.40-10.42)
1.40 (0.93-2.12)
1.01 (0.51-1.98)
3.08 (1.13-8.45)

24 (2.5)
21 (7.4)
5.06 (2.78-9.23)
3.08 (1.48-6.45)
10.36 (3.56-30.18)
2.50 (1.50-4.16)
1.73 (0.82-3.66)
6.19 (2.09-18.31)

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
0.070
<0.001

10 (0.8)
6 (1.1)
1.00
1.00
1.00
1.00
1.00
1.00

47 (0.9)
43 (1.6)
1.18 (0.69-2.01)
1.06 (0.53-2.09)
1.40 (0.59-3.28)
1.03 (0.60-1.76)
0.90 (0.45-1.79)
1.26 (0.53-2.97)

15 (1.6)
12 (4.2)
2.57 (1.38-4.77)
1.92 (0.86-4.28)
3.93 (1.47-10.46)
1.78 (0.93-3.39)
1.28 (0.56-2.90)
2.92 (1.07-7.97)

0.103
0.006
0.002
0.095
0.004
0.057
0.493
0.025

16 (1.3)
16 (3.0)
1.00
1.00
1.00
1.00
1.00
1.00

148 (2.7)
121 (4.4)
1.78 (1.23-2.57)
2.08 (1.24-3.49)
1.34 (0.93-1.94)
1.56 (1.08-2.25)
1.78 (1.06-2.99)
1.33 (0.79-2.25)

43 (4.5)
17 (6.0)
2.78 (1.81-4.27)
3.42 (1.93-6.08)
1.64 (0.88-3.06)
2.01 (1.29-3.13)
2.40 (1.34-4.31)
1.55 (0.77-3.12)

<0.001
0.045
<0.001
<0.001
0.067
0.002
0.003
0.205

P value for trial
heterogeneity of
hazard ratios

0.006

0.002

0.064

0.032

0.178

0.153

0.484

0.399

0.517

0.633

CI denotes confidence interval.
*Modeling of the pooled participants from SPRINT and ACCORD, with stratified baseline hazard functions by trial.
†Modeling separately of the participants from SPRINT or ACCORD.
‡Adjusted for age, race, sex, Framingham Risk Score, baseline systolic and diastolic blood pressure, use of
antihypertensive medication before randomization, smoking status, aspirin use, estimated glomerular filtration rate,
history of clinical/subclinical cardiovascular disease, total cholesterol, high-density lipoprotein, triglycerides,
glucose, urine albumin/creatinine ratio, body-mass index, statin use, treatment assignment, number of
antihypertensive medications used, and estimated achieved 1-year SBP.

Figure S1. Hazard ratios of post 1-year outcomes associated with estimated SBP achieved at 1 year for
SPRINT and ACCORD, using restricted cubic splines.
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Figure S2. Distribution of visit-to-visit variability classes for participants from the intensive and standard
treatment groups of SPRINT and ACCORD. \
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Bars represent percentages of participants assigned to 3 classes of visit-to-visit variability.

Figure S3. Hazard ratios of post 1-year outcomes associated with intensive versus standard treatment for
classes of visit-to-visit variability in (A) SPRINT and (B) ACCORD.*
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* HR denotes the hazard ratio and CI the confidence interval.
Hazard ratios were adjusted for age, race, sex, Framingham Risk Score, baseline systolic and diastolic blood
pressure, use of antihypertensive medication before randomization, smoking status, aspirin use, estimated
glomerular filtration rate, history of clinical/subclinical cardiovascular disease, total cholesterol, high-density
lipoprotein, triglycerides, glucose, urine albumin/creatinine ratio, body-mass index, statin use, number of
antihypertensive medications used, visit adherence, and estimated achieved 1-year SBP. All interactions were not
significant for visit-to-visit variability class and each outcome except for heart failure in SPRINT (class 2 vs class 1
[p=0.062], and class 3 vs class 1 [p=0.088]).
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